Fibrocystic Breast Disease

TUESDAY, Sept. 3, 2024 -- A significant number of women stop getting regular mammograms after being frightened by a “false positive” scan that incorrectly suggests they have breast cancer, a new study finds. About 77% of women return for a regular mammogram after a negative result that shows they’re clearly cancer-free, researchers reported Sept. 2 in the Annals of Internal Medicine . But that percentage drops to 61% if a woman receives a false-positive reading, which requires a follow-up mammogram to rule out or verify breast cancer. What’s more, only 56% of women who receive false-positive results on two consecutive mammograms returned for regular screenings. Researchers also found that only 67% of women returned for routine mammography if a false-positive reading requires a biopsy to rule out cancer. “The finding raises concerns about the potential unintended consequence of false-positive results, where women may avoid screening mammograms in the future,” said lead investigator Diana Miglioretti , chief of the University of California, Davis' Division of Biostatistics. It’s crucial that women get their regularly scheduled mammogram, especially if they have a false-positive scare, Miglioretti stressed. “It is important for women with false-positive results to continue screening every one to two years,” Miglioretti said in a university news release. “Having a false-positive result, especially if it results in a diagnosis of benign breast disease, is associated with an increased risk of being diagnosed with breast cancer in the future.” For the study, researchers analyzed data on more than 3.5 million screening mammograms conducted in the United States between 2005 and 2017, involving more than 1 million women ages 40 to 73. About 10% of the time, additional imaging is needed to get a better look at an abnormal finding on a screening mammogram, researchers said in background notes. After 10 years of annual screenings, 50% to 60% of women can expect at least one false-positive, and 7% to 12% a false positive with a biopsy recommendation. Any abnormal result from a mammogram causes understandable anxiety and concern, researchers said. “It’s important to understand that most women recalled for additional imaging due to a finding on a screening mammogram do not have breast cancer,” Miglioretti said. “They should try not to be worried if they are recalled for additional work-up. it is a normal and common part of the screening process.” Asian and Hispanic woman were the least likely to return for mammograms following a false positive result, researchers found. Women who are anxious about waiting for a mammogram result can request an on-the-spot interpretation of their scan, Miglioretti said. Some imaging facilities provide this service along with a same-day diagnostic work-up if there’s an abnormal finding. Doctors also need to do a better job counseling patients following a false positive result, Miglioretti added. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Rare disease charity PTEN Research Foundation welcomes two new senior leaders from the pharmaceutical industry, Professor Sir Mene Pangalos and Dr Donald Ogilvie to the Foundation’s Scientific Advisory Board (SAB). By strengthening its scientific oversight, the Foundation hopes to further progress and accelerate its mission to fund and facilitate research that will lead to better treatments and improved outcomes for people with PTEN Hamartoma Tumour Syndrome (PHTS). CHELTENHAM, England--(BUSINESS WIRE)-- PTEN Research Foundation, a charity which funds and facilitates research with the aim of developing new and better treatments for the rare disease PTEN Hamartoma Tumour Syndrome (PHTS), today announced that it has further strengthened its scientific oversight of activities with two new senior leaders, Dr Donald Ogilvie and Prof Sir Mene Pangalos, joining the Foundation’s Scientific Advisory Board (SAB). This press release features multimedia. View the full release here: Prof Sir Menelas (Mene) Pangalos DSc PhD FRSB FMedSci HonFBPhS FRS (Photo: Business Wire) “We are honoured that two such senior leaders with a wealth of drug development experience have agreed to join the Foundation’s Scientific Advisory Board,” said Thomas Pepper, Chief Executive of PTEN Research Foundation. “The SAB has a critical role in steering the Foundation’s scientific strategy and we continue to be privileged that senior leaders from pharma and biotech, as well as academic physicians and scientists with a deep knowledge of PHTS, have been willing to join the Board and guide the Foundation’s mission.” PHTS is a condition caused by an alteration in the PTEN gene. Such an alteration, which may be inherited from the mother or father, or occur spontaneously during embryonic development, can affect multiple organs and result in a variety of symptoms. These include macrocephaly (enlarged head circumference), learning difficulties, autism spectrum disorder, vascular anomalies (abnormal growth of the blood vessels), gastrointestinal polyps (growths in the gut), and hamartomas (benign lesions of the skin and other tissues). In addition, people with PHTS have a significantly increased risk of developing cancer of the breast, thyroid and endometrium (lining of the womb). Notes for Editors About Dr Donald Ogilvie MA DPhil Donald is an independent scientific consultant providing expert advice on cancer drug discovery to academic, industrial, and venture capital organisations. Donald obtained an MA in Biochemistry at the University of Oxford, UK, in 1980, before working at the John Radcliffe Hospital, Oxford, for eight years on the role of proteases in cancer, then on inherited connective tissue disorders. The latter was the basis of his DPhil degree. In 1988, Donald joined ICI which subsequently became Zeneca then AstraZeneca. For most of his twenty-year career in the pharmaceutical industry, he worked on cancer drug discovery and early clinical development projects. He was directly responsible for the delivery of ten novel cancer development compounds, several of which have progressed to phase II & III clinical trials and two, so far, to regulatory approval. Between 2009 and 2017, Donald set up and led the academic Drug Discovery Unit at the Cancer Research UK Manchester Institute (University of Manchester, UK). Under his leadership, the team built a drug discovery infrastructure and a leading cancer project portfolio. During this period, three projects, including one with a development compound, were successfully licensed to downstream partners. Donald is a co-author on more than ninety peer-reviewed academic publications. About Prof Sir Menelas (Mene) Pangalos DSc PhD FRSB FMedSci HonFBPhS FRS Until Spring 2024 Mene held the role of Executive Vice President, Research and Development at AstraZeneca being responsible for R&D from discovery through to late-stage development covering Cardiovascular, Renal, Metabolism, Respiratory, Immunology, Microbial Science and Neuroscience areas. Prior to this, he served as Executive Vice-President of AstraZeneca’s Innovative Medicines & Early Development Biotech Unit and Global Business Development. During his time with AstraZeneca, Mene led the transformation of R&D productivity through the development and implementation of the “5R” framework resulting in a greater than four-fold increase in success rates compared to industry averages. In parallel, he has championed an open approach to working with academic and other external partners, changing the nature of academic-industry collaboration. In addition, Mene led and oversaw AstraZeneca’s R&D response to COVID-19; maintaining existing clinical trials and delivery of medicines to patients, responding to the UK government’s call for supporting its national testing effort, and discovering and developing new preventative and treatment approaches to the disease. This work involved partnering with Oxford University in the global development of a vaccine and ensuring broad and equitable access at no profit during the pandemic, the discovery and development of a long-acting antibody combination for those who could not be vaccinated, as well as exploring AstraZeneca’s existing portfolio as potential treatment options against the disease. The team were awarded the Copley Medal by the Royal Society in 2023. Mene previously held senior R&D roles at Wyeth and GSK. Mene holds Honorary Doctorates from Glasgow University and Imperial College, London, is a Fellow of the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge and is a Visiting Professor at The Wolfson Centre at King’s College. He co-chairs the UK Life Sciences Council Expert Group on Innovation, Clinical Research and Data and is a member of the Life Sciences Industrial Strategy Implementation Board. He is also on the Boards of The Francis Crick Institute and The Judge Business School, Cambridge University, and is a member of the Life Sciences Vision Advisory Group. Mene was awarded the 2019 Prix Galien Medal, Greece for his scientific research and named Executive of the Year at the 2019 Scrip Awards. In 2019, Mene was awarded the honour of a Knighthood by Queen Elizabeth II for his services to UK science. In 2021 Mene was awarded an Honorary Fellowship of the British Pharmacological Society. In 2022 Mene was elected as a Fellow of The Royal Society and an honorary professor of Cambridge University Medical School. About PHTS PHTS is a rare genetic disorder caused by alteration in the PTEN (phosphatase and tensin homolog) gene that results in a variety of symptoms in multiple organs. These alterations, which may be inherited from the mother or father or occur spontaneously during embryonic development, can result in a variety of symptoms. These include macrocephaly (enlarged head circumference), learning difficulties, autism spectrum disorder, vascular anomalies (abnormal growth of the blood vessels), gastrointestinal polyps (growths in the gut), and hamartomas (benign lesions of the skin and other tissues). In addition, people with PHTS have an increased lifetime risk of developing cancer, particularly breast, thyroid, and endometrial (lining of the womb) cancer. Estimating the prevalence of PHTS is complex due to the varied presentations and diagnoses patients can have and because some features (e.g. benign breast lesions) also commonly occur in the general population. The prevalence of PHTS is estimated to be about 1 in 200,000, although this is likely to be an underestimate. There are currently no health authority-approved treatments specific to PHTS, and clinical management consists mainly of cancer surveillance and supportive care. The need for cancer surveillance and lifelong supportive care places a high burden on affected individuals, their families and on healthcare systems. About PTEN Research Foundation PTEN Research Foundation was established as a charity under English law in 2017 (charity number 1173589). The Foundation’s mission is to fund and facilitate research that will lead to new and better treatments for individuals with PHTS. PTEN Research Foundation aims to have transformative therapies available as treatment options for people with PHTS within 10 years. The Foundation’s strategy is centred on the generation of preclinical and clinical evidence that will enable the Foundation, and others (both academic collaborators and industry), to develop treatment options for people with PHTS.

CHICAGO, Aug. 8, 2023 /PRNewswire/ -- In the near future, the breast biopsy devices industry is poised to witness remarkable advancements driven by innovative technologies and a growing emphasis on early detection and precise diagnosis of breast conditions. Rapid progress in imaging techniques, such as 3D mammography and molecular imaging, will catalyze the demand for minimally invasive and highly accurate biopsy devices. These devices will offer improved targeting capabilities, real-time imaging guidance, and enhanced tissue sampling methods, ultimately enhancing diagnostic accuracy and patient outcomes. Additionally, the integration of artificial intelligence and machine learning algorithms will further refine the biopsy process by providing predictive insights and aiding pathologists in analyzing tissue samples. As healthcare systems prioritize personalized medicine, the breast biopsy devices sector will play a pivotal role in revolutionizing breast health management through its convergence of cutting-edge technology and patient-centered care. Breast Biopsy Devices Market in terms of revenue was estimated to be worth $1.6 billion in 2023 and is poised to reach $2.6 billion by 2028, growing at a CAGR of 10.0% from 2023 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market include the growing prevalent cases of breast cancer, the increasing number of breast cancer screening programs, the growing demand for minimally invasive and non-invasive procedures, and the improved reimbursement scenario. Download an Illustrative overview: Browse in-depth TOC on "Breast Biopsy Devices Market" 140 - Tables 45 - Figures 200 - Pages Breast Biopsy Devices Market Scope: Type segment to register significant growth rate over the forecast period of 2023-2028. Based on the type, the global breast biopsy devices market is segmented into biopsy needles, guidance systems, localization wires, assay kits, liquid biopsy instruments, biopsy tables, and other devices. The assay kits segment is expected to grow at the highest CAGR during the forecast period. In 2022, the biopsy needle segment accounted for the highest breast biopsy devices market share. Procedure segment to register significant growth rate over the forecast period of 2023-2028. Based on the procedure, the breast biopsy devices market is segmented into needle open surgical breast biopsy, breast biopsy, and liquid breast. The liquid breast biopsy segment is anticipated to register the highest growth rate over the forecast period. However, the needle breast biopsy segment accounted for the highest market share in the breast biopsy devices market in 2022. The early cancer screening segment accounted for the largest share of the breast biopsy market by application in 2022. Based on application, the market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. Early cancer screening accounted for the largest share of the market in 2022. However, the therapy selection segment is expected to grow at the highest CAGR during the forecast period. Factors such as the rising occurrence of breast cancer cases, growing awareness of breast cancer, and supportive government initiatives for breast cancer care and treatment are expected to influence the demand for breast biopsy devices. The hospital and clinics segment accounted for the largest share of the breast biopsy devices market, by end-user, in 2022. Based on the end user, the breast biopsy devices market is segmented into hospitals & surgical centers, breast care centers, and imaging clinics & diagnostic centers. The hospitals & surgical centers segment accounts for the largest share of the market in 2022. Factors attributing to the increasing number of breast diagnostic procedures performed in hospitals, the growing inclination of hospitals toward automation and digitization of radiology patient workflow, and the rising adoption of technologically advanced systems in hospitals to improve patient care quality are driving this segment's growth. The North American market is to register significant growth in the market during the forecast period. The North American breast biopsy devices market is estimated to grow significantly from 2023 to 2028. factors such as ongoing technological advancements, rising breast cancer incidence rates, favorable reimbursement scenarios, and new breast density notification laws drive market growth in North America. This region has a rise in healthcare investment and expenditure, offering significant growth opportunities for the key players. Request Sample Pages: Breast Biopsy Devices Market Dynamics: Drivers: Increasing number of breast cancer screening programs Restraints: Risk of infections associated with the use of biopsy needles Opportunities: Emergence of liquid biopsy and promising clinical trials Challenges: Underdeveloped Healthcare Infrastructure and Dearth of Resources in Developing Countries Key Market Players: As of 2022, prominent players in the breast biopsy devices market are Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Medtronic (IRL), Merit Medical Systems (US), Menarini-Silicon Biosystems (ITL), Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), Biocept, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Qiagen (Germany) and Exact Sciences Corporation (US). Recent Developments: Hologic, Inc, an innovative medical technology company primarily focused on improving women's health, announced today that it has completed the purchase of SOMATEX Medical Technologies GmbH; the deal size is $64 million. In 2022 Danaher Corporation launched Mammotome Revolve EX Dual Vacuum-Assisted Breast Biopsy System, the first vacuum-assisted biopsy device designed specifically for the excision of benign breast lesions and is twice as fast as traditional vacuum-assisted breast biopsy systems. Argon Medical Devices announced the launch of the SuperCore advantage semi-automatic biopsy instrument's newest addition to its soft tissue biopsy product portfolio in the united states. The next-generation soft tissue biopsy instrument provides a superior volume of tissue samples. Collecting more tissue volume may increase the likelihood of an accurate diagnosis. Get 10% Free Customization on this Report: Breast Biopsy Devices Market Advantages: Early Detection: Breast biopsy devices enable the early detection of suspicious lesions or abnormalities in breast tissue, allowing for prompt diagnosis and intervention. Minimally Invasive: These devices offer minimally invasive alternatives to surgical biopsies, reducing patient discomfort, scarring, and recovery time. Precision Targeting: Advanced imaging technologies incorporated in these devices allow for precise targeting of the specific area of concern, ensuring accurate tissue sampling. Reduced Procedure Time: Modern biopsy devices streamline procedures, leading to shorter procedural times, increased patient throughput, and efficient resource utilization for healthcare facilities. Improved Patient Experience: Minimally invasive procedures and shorter recovery periods contribute to a better patient experience and higher patient satisfaction rates. Cost-Effectiveness: Minimally invasive biopsies with these devices often lead to reduced healthcare costs compared to surgical alternatives, as they require fewer resources and less hospitalization time. Real-Time Imaging Guidance: Integration of real-time imaging guidance enhances the accuracy of tissue sampling and reduces the likelihood of inconclusive results. Diagnostic Accuracy: The use of advanced technologies, such as molecular imaging and artificial intelligence, enhances diagnostic accuracy, reducing the need for multiple procedures and interventions. Customized Treatment Plans: Accurate biopsy results enable healthcare professionals to create personalized treatment plans, optimizing patient care and outcomes. Research and Development: The ongoing innovation in breast biopsy device technology fuels research and development efforts, contributing to continuous improvements in diagnostic capabilities. Reduced Anxiety: Early and accurate diagnosis through these devices can alleviate patient anxiety by providing a clear understanding of their condition and appropriate treatment pathways. Screening Programs: Breast biopsy devices play a crucial role in supporting breast cancer screening programs, enabling efficient follow-up on suspicious findings from mammograms. Healthcare Resource Optimization: By reducing unnecessary surgeries and interventions, these devices help optimize the allocation of healthcare resources. Enhanced Medical Training: Modern biopsy devices are often integrated with training features, enabling medical professionals to acquire and enhance their skills in using these devices effectively. Global Impact: The widespread availability and adoption of breast biopsy devices contribute to improving breast healthcare on a global scale, especially in regions with limited access to specialized medical facilities. These advantages collectively underscore the significant role that breast biopsy devices play in improving patient care, enhancing diagnostic capabilities, and shaping the future of breast health management. Related Reports: Breast Imaging Market - Global Forecasts to 2028 Aspiration Needles Market - Global Forecasts to 2027 Liquid Biopsy Market - Global Forecasts to 2027 Cancer Diagnostics Market - Global Forecasts to 2026 Womens Health Diagnostics Market - Global Forecasts to 2025 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: Visit Our Website: Content Source: Logo: SOURCE MarketsandMarkets